Herpes Zoster Ophthalmicus

Prim Care. 2015 Sep;42(3):285-303. doi: 10.1016/j.pop.2015.05.007.


Herpes zoster is a commonly encountered disorder. It is estimated that there are approximately 1 million new cases of herpes zoster in the United States annually, with an incidence of 3.2 per 1000 person-years. Patients with HIV have the greatest risk of developing herpes zoster ophthalmicus compared with the general population. Other risk factors include advancing age, use of immunosuppressive medications, and primary infection in infancy or in utero. Vaccination against the virus is a primary prevention modality. Primary treatments include antivirals, analgesics, and anticonvulsants. Management may require surgical intervention and comanagement with pain specialists, psychiatrists, and infectious disease specialists.

Keywords: HZO; Herpes zoster ophthalmicus; Ophthalmic zoster; Shingles; Shingles complications.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones
  • Antiviral Agents / therapeutic use
  • Diagnosis, Differential
  • Herpes Zoster Ophthalmicus / diagnosis*
  • Herpes Zoster Ophthalmicus / drug therapy
  • Herpes Zoster Ophthalmicus / physiopathology
  • Herpes Zoster Ophthalmicus / prevention & control*
  • Herpes Zoster Vaccine / administration & dosage*
  • Herpes Zoster Vaccine / immunology
  • Humans
  • Incidence
  • Pain Management / methods
  • Primary Health Care*
  • Quality of Life
  • Referral and Consultation
  • Risk Factors
  • Self Care
  • United States


  • Adrenal Cortex Hormones
  • Antiviral Agents
  • Herpes Zoster Vaccine